ALK-Abelló A/S
ALK-Abelló A/S
- Market cap
- $7.27B
- P/E ratio
- 37.79
Your view on AKBLF
Overview
What the company does, where it operates, and who runs it.
About ALK-Abelló A/S
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Peter Halling
- Headquarters
- Boge Alle 6-8, Horsholm, DK
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Peter Halling
- Headquarters
- Boge Alle 6-8, Horsholm, DK
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar.
It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma.
ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for ALK-Abelló A/S from FRC's valuation model, read against the market price. AKBLF last traded at $36.10, 37.8× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for ALK-Abelló A/S. Starting points for ALK-Abelló A/S: P/E 37.8, EPS $6.33, beta 0.58 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for ALK-Abelló A/S. ALK-Abelló A/S does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for ALK-Abelló A/S. Trailing twelve-month EPS for ALK-Abelló A/S stands at $6.33. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for ALK-Abelló A/S. ALK-Abelló A/S has reported as a listed company since 2009. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| MSLESatellos Bioscience Inc. | Healthcare | NASDAQ | $7.3M | ||
| MSRMMushrooms Inc | Healthcare | OTC | $233,727 | ||
| MTNBMatinas BioPharma Holdings, Inc. | Healthcare | AMEX | $341,620 | ||
| MTVAMetaVia Inc. | Healthcare | NASDAQ | $6.8M | ||
| MXCTMaxCyte, Inc. | Healthcare | NASDAQ | $141.5M | ||
| MYMXMymetics Corporation | Healthcare | OTC | $46 | ||
| MYNDFMYND Life Sciences Inc. | Healthcare | OTC | $657,843 | ||
| NAGENiagen Bioscience Inc | Healthcare | NASDAQ | $145.7M | ||
| NAMSNewAmsterdam Pharma Company N.V. | Healthcare | NASDAQ | $2.2B | ||
| NAMSWNewAmsterdam Pharma Company N.V. | Healthcare | NASDAQ | $1.8B | ||
| NAUTNautilus Biotechnology, Inc. | Healthcare | NASDAQ | $270.0M | ||
| NAVBQNavidea Biopharmaceuticals, Inc. | Healthcare | OTC | $100 | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for ALK-Abelló A/S. Coverage tracks ALK-Abelló A/S within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of ALK-Abelló A/S.